A Double-Blinded Prospective Randomized Clinical Trial Comparing Euploidy Rates Among Embryos Created From Sibling Oocytes Exposed to Sperm After Ultrashort Abstinence Compared With Standard Abstinence

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This research is being done to determine if producing sperm after an ultrashort period of abstinence (1 hour of abstinence) will be effective in improving the rates of embryos with normal chromosomes (structures that carry genetic information) during in vitro fertilization (IVF) treatment. The investigators hypothesize that a shorter period of abstinence is effective at improving rates of normal chromosomes among embryos.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 42
Healthy Volunteers: f
View:

• Subjects are nonpregnant females ≥ 18 years and ≤ 42 years of age.

• Subjects obtain greater than or equal to 6 mature oocytes at the time of oocyte retrieval for ICSI or greater than or equal to 8 oocytes at the time of oocyte retrieval for standard insemination.

• Subjects are utilizing standard insemination or ICSI for fertilization.

• Subjects are undergoing PGT-A (PGT for aneuploidy) or PGT-M (PGT for monogenic disorders).

• Subjects are willing to comply with study protocol and procedures and provide written informed consent.

Locations
United States
Connecticut
The Center for Advanced Reproductive Services, P.C.
RECRUITING
Farmington
Time Frame
Start Date: 2025-07
Estimated Completion Date: 2027-06
Participants
Target number of participants: 187
Treatments
Experimental: Ultrashort abstinence
Half of participants eggs will be exposed to sperm produced after ultrashort abstinence (1 hour of abstinence).
Active_comparator: Standard abstinence
Half of participants eggs will be exposed to sperm produced after standard abstinence (2-5 days of abstinence).
Related Therapeutic Areas
Sponsors
Collaborators: The Center for Advanced Reproductive Services, P.C.
Leads: UConn Health

This content was sourced from clinicaltrials.gov